Business Description
Exicure Inc
NAICS : 325411
SIC : 2834
ISIN : US30205M2008
Description
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.33 | |||||
| Equity-to-Asset | 0.55 | |||||
| Debt-to-Equity | 0.72 | |||||
| Debt-to-EBITDA | 1.39 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -12.15 | |||||
| Beneish M-Score | 12.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 110 | |||||
| 3-Year EPS without NRI Growth Rate | 65.6 | |||||
| 3-Year Book Growth Rate | -52.6 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 11.72 | |||||
| 9-Day RSI | 20.99 | |||||
| 14-Day RSI | 28.03 | |||||
| 6-1 Month Momentum % | 4.65 | |||||
| 12-1 Month Momentum % | -40.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.56 | |||||
| Quick Ratio | 2.56 | |||||
| Cash Ratio | 1.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.1 | |||||
| Shareholder Yield % | 26.86 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 13.49 | |||||
| Net Margin % | 12.88 | |||||
| FCF Margin % | -93.05 | |||||
| ROE % | 41.75 | |||||
| ROA % | 11.72 | |||||
| ROIC % | 14.46 | |||||
| ROC (Joel Greenblatt) % | 32.68 | |||||
| ROCE % | 20.58 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 0.27 | |||||
| PE Ratio without NRI | 0.27 | |||||
| PS Ratio | 0.1 | |||||
| PB Ratio | 0.41 | |||||
| Price-to-Tangible-Book | 0.4 | |||||
| EV-to-EBIT | 2.7 | |||||
| EV-to-EBITDA | 1.76 | |||||
| EV-to-Revenue | 0.37 | |||||
| EV-to-FCF | -0.39 | |||||
| Price-to-Graham-Number | 0.07 | |||||
| Earnings Yield (Greenblatt) % | 37 | |||||
| FCF Yield % | -524.93 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers